首页> 外文期刊>European archives of psychiatry and clinical neuroscience >Antidepressant effect of repetitive transcranial magnetic stimulation is not impaired by intake of lithium or antiepileptic drugs
【24h】

Antidepressant effect of repetitive transcranial magnetic stimulation is not impaired by intake of lithium or antiepileptic drugs

机译:重复经颅磁刺激的抗抑郁作用不会因摄入锂或抗癫痫药物而受损

获取原文
获取原文并翻译 | 示例
获取外文期刊封面目录资料

摘要

Introduction The effect of concomitant medication on repetitive transcranial magnetic stimulation (rTMS) outcomes in depression remains understudied. Recent analyses show attenuation of rTMS effects by antipsychotic medication and benzodiazepines, but data on the effects of antiepileptic drugs and lithium used as mood stabilizers or augmenting agents are sparse despite clinical relevance. Preclinical electrophysiological studies suggest relevant impact of the medication on treatment, but this might not translate into clinical practice. We aimed to investigate the role of lithium (Li), lamotrigine (LTG) and valproic acid (VPA) by analyzing rTMS treatment outcomes in depressed patients. Methods 299 patients with uni- and bipolar depression treated with rTMS were selected for analysis in respect to intake of lithium, lamotrigine and valproic acid. The majority (n = 251) were treated with high-frequency (10-20 Hz) rTMS of the lDLPFC for an average of 17 treatment sessions with a figure-of-8 coil with a MagVenture system aiming for 110 resting motor threshold, and smaller groups of patients were being treated with other protocols including intermittent theta-burst stimulation and bilateral prefrontal and medial prefrontal protocols. For group comparisons, we used analysis of variance with the between-subjects factor group or Chi-Square Test of Independence depending on the scales of measurement. For post-hoc tests, we used least significant difference (LSD). For differences in treatment effects between groups, we used an ANOVA with the between-subjects factor group (groups: no mood stabilizer, Li, LTG, VPA, Li + LTG) the within-subjects factor treatment (pre vs. post treatment with rTMS) and also Chi-Square Tests of independence for response and remission. Results Overall, patients showed an amelioration of symptoms with no significant differences for the main effect of group and for the interaction effect treatment by group. Based on direct comparisons between the single groups taking mood stabilizers against the group taking no mood stabilizers, we see a superior effect of lamotrigine, valproic acid and combination of lithium and lamotrigine for the response and remission rates. Motor threshold was significantly and markedly higher for patients taking valproic acid. Conclusion Being treated with lithium, lamotrigine and valproic acid had no relevant influence on rTMS treatment outcome. The results suggest there is no reason for clinicians to withhold or withdraw these types of medication from patients who are about to undergo a course of rTMS. Prospective controlled work on the subject is encouraged.
机译:引言 伴随用药对抑郁症重复经颅磁刺激 (rTMS) 结果的影响仍未得到充分研究。最近的分析显示,抗精神病药物和苯二氮卓类药物对 rTMS 的影响减弱,但关于抗癫痫药物和用作情绪稳定剂或增强剂的锂的作用的数据很少,尽管具有临床相关性。临床前电生理学研究表明药物对治疗有相关影响,但这可能不会转化为临床实践。我们旨在通过分析抑郁症患者的 rTMS 治疗结果来研究锂 (Li)、拉莫三嗪 (LTG) 和丙戊酸 (VPA) 的作用。方法 选取299例接受rTMS治疗的单相和双相抑郁患者,分析锂、拉莫三嗪和丙戊酸的摄入情况。大多数 (n = 251) 接受 lDLPFC 的高频 (10-20 Hz) rTMS 治疗,平均 17 次治疗,使用 8 字形线圈和 MagVenture 系统,旨在达到 110% 静息运动阈值,较小的患者组正在接受其他方案治疗,包括间歇性 θ 爆发刺激和双侧前额叶和内侧前额叶方案。对于组比较,我们根据测量量表使用受试者间因子组或独立性卡方检验的方差分析。对于事后检验,我们使用了最小显著性差异(LSD)。对于组间治疗效果的差异,我们使用方差分析与受试者间因子组(组:无情绪稳定剂、Li、LTG、VPA、Li + LTG)、受试者内因素治疗(rTMS治疗前与治疗后)以及反应和缓解独立性的卡方检验。结果 总体来看,患者症状有所改善,组间主效应和组间交互效应治疗差异无统计学意义。基于服用情绪稳定剂的单组与不服用情绪稳定剂的组之间的直接比较,我们看到拉莫三嗪、丙戊酸以及锂和拉莫三嗪组合对反应和缓解率的效果更好。服用丙戊酸的患者的运动阈值显着且显着升高。结论 锂、拉莫三嗪和丙戊酸治疗对rTMS治疗结局无相关影响。结果表明,临床医生没有理由对即将接受 rTMS 疗程的患者扣留或撤回这些类型的药物。鼓励对该主题进行前瞻性的受控工作。

著录项

获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号